Drugs / Dorzolamide-timol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02571972 | Feb → Sep 2015 | diabetic macular edema, retinal vein occlusion, wet macular degeneration | Wills Eye | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dorzolamide-timol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02571972 ↗ |
| Known as | dorzolamide hydrochloride-timolol maleate | “OBJECTIVE: To evaluate the effect of topical dorzolamide hydrochloride-timolol maleate on anatomic and functional outcomes in eyes with neovascular AMD and incomplete response...” PMID 26914218 ↗ Apr 2016 |
| Route | Topical | “On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration” NCT02571972 ↗ |